Bruker

The company reported total revenues of $431.7 million for the three months ended March 31, beating analysts' consensus estimate of $417.4 million.

The companies are aiming to codevelop, comarket, and improve the integration of the Evosep One LC system with Bruker's timsTOF Pro mass spec.

The firm posted revenues of $530.5 million, with organic growth at 4 percent and acquisitions and currency effects adding 4 percent and 5 percent, respectively.

Companies in the life science tools and molecular diagnostics spaces provided updates on their businesses at the 36th annual JP Morgan Healthcare Conference this week in San Francisco.

Researchers found that 98 percent of the identifications the system provided were correct, indicating the usefulness of the platform in clinical mycology.

The company posted revenues of $435.6 million, up from $393.9 million in Q3 2016, beating the consensus Wall Street estimate of $414.6 million.

Areas like pharma and food and water testing could prove growth areas for the platform as instrument sales growth slows in the clinic microbiology space.

The company reported revenues of $414.9 million as acquisitions boosted revenues 6 percent and foreign exchange rates lowered them by 2 percent.

The platform received 510(k) clearance from the US Food and Drug Administration for the expanded identification of mycobacteria, Nocardia, and molds.

Pages

Researchers have sequenced the northern white rhinoceros to gauge whether it could be brought back from the edge of extinction, the New York Times reports.

Bavaria expands its forensic genetic analyses to include DNA phenotyping, raising discrimination concerns.

Tufts University researchers found a role for miRNA in transmitting stress between generations, the Economist reports.

In Science this week: gut microbiome influences liver cancer growth, spread; and more.